Related Experiment Videos
Nf1 and Gmcsf interact in myeloid leukemogenesis
R A Birnbaum1, A O'Marcaigh, Z Wardak
1Department of Pediatrics, University of California, San Francisco 94143-0519, USA.
Molecular Cell
|March 11, 2000
Summary
Granulocyte-macrophage colony-stimulating factor (GM-CSF) drives myeloproliferative disorders in NF1 patients. Eliminating GM-CSF in mice with Nf1 mutations prevents these disorders, highlighting GM-CSF
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The NF1 gene encodes neurofibromin, a GTPase-activating protein (GAP) crucial for regulating p21ras (Ras) signaling.
- Neurofibromin deficiency (NF1) predisposes individuals to juvenile myelomonocytic leukemia (JMML).
- Nf1-deficient mice exhibit myeloproliferative disorders (MPD) similar to human JMML.
Purpose of the Study:
- To investigate the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the development of NF1-associated MPD.
- To determine if GM-CSF is essential for the excessive proliferation of Nf1-deficient hematopoietic cells in vivo.
Main Methods:
- Generation of hematopoietic cells lacking both Nf1 and Gmcsf.
- Assessment of MPD development in recipient mice engrafted with Nf1-/- Gmcsf-/- cells.
- Evaluation of hypersensitivity to GM-CSF in Nf1-deficient cells.
Main Results:
- GM-CSF plays a critical role in initiating and sustaining the MPD in the Nf1-deficient mouse model.
- Recipients engrafted with Nf1-/- Gmcsf-/- hematopoietic cells did not develop MPD.
- Nf1-/- Gmcsf-/- hematopoietic cells remained hypersensitive to exogenous GM-CSF stimulation.
Conclusions:
- GM-CSF is a key driver of NF1-associated myeloproliferative disorders.
- Targeting GM-CSF may offer a therapeutic strategy for NF1-related leukemias.
- Understanding the interplay between NF1 and GM-CSF signaling is crucial for treating these conditions.